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Ala: L-Alanine Asn: L-Asparagine 
Arg: L-Arginine Asp: L-Aspartic acid 
Cys: L-Cysteine Glu: L-Glutamic acid 
Gly: Glycine His: L-Histidine 
Ile: L-Isoleucine Leu: L-Leucine 
Lys: L-Lysine Asn: L-Methionine 
Phe: L-Phenylalanine Pro: L-Proline 
Ser: L-Serine Thr: L-Threonine 
Trp: L-Tryptophan Tyr: L-Tyrosine 
Val: L-Valine 
 
ATP6: ATP synthase subunit protein 6 
ATP8: ATP synthase subunit protein 8 
[Ca2+]i: Concentration of intracellular free Ca2+ 
CD: Circular dichroic 
COX1: Cytochrome c oxidase subunit I 
COX2: Cytochrome c oxidase subunit II 
COX3: Cytochrome c oxidase subunit III 
CysH: Cyclosporin H 
EC50: Effective concentration 
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EM: Electron microscopy 
fMLF: Formyl-Met-Leu-Phe 
FPR1: Formyl peptide receptor 1 
FPR2: Formyl peptide receptor 2 
HBHS: HEPES-buffered Hank's solution 
IL-8: Interleukin 8 




mtDNA: Mitochondrial DNA 
mtDAMPs: Mitochondrial damage-associated molecular patterns 
ND1: NADH dehydrogenase subunit 1 
ND2: NADH dehydrogenase subunit 2 
ND3: NADH dehydrogenase subunit 3 
ND4L: NADH dehydrogenase subunit 4L 
ND4: NADH dehydrogenase subunit 4 
ND5: NADH dehydrogenase subunit 5 
ND6: NADH dehydrogenase subunit 6 















Neutrophils are a type of leukocytes that are involved in the innate defense system 
[1–3]. Neutrophils comprise the majority of peripheral leukocytes and normally exist in 
bloodstream to monitor for infection and tissue damage. When tissue injury occurs due 
to bacterial infections or internal tissue damage, neutrophils immediately migrate to and 
infiltrate injury sites. Infiltrated neutrophils are then activated and exert their functions 
including superoxide production and phagocytosis of invading bacterial components 
and toxic substances. 
Bacterial N-formylated proteins and peptides are well known as chemoattractants 
for neutrophils. In 1975, Schiffmann et al. found that bacterial N-formylated proteins 
and peptides induced neutriphil migration and activation [4]. Subsequently, various 
bacterial N-formylated peptides including formyl-Met-Leu-Phe (fMLF) were identified 
from bacterial culture supernatants as chemoattractants for neutrophils [5, 6]. Moreover, 
Carp demonstrated that endogenous N-formylated proteins or peptides in mitochondria 
possibly induce migration of neutrophils [7], although such neutrophil-migrating 
N-formylated proteins and peptides have not been molecularly identified.  
In addition to such N-formylated proteins and peptides, complement-derived 
factors have been also identified as chemoattractants for neutrophils [8, 9]. Indeed, 
several complement proteins are cleaved by complement system, and various fragment 
peptides are produced during activation of the complement system by invading 
microbes. Among those fragments, component 3a and 5a have been found to 
chemoattract neutrophils to promote inflammatory reactions [8, 9]. Moreover, it has 
been shown that some CXC chemokines such as IL-8 promote migration and activation 
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of neutrophils [10, 11]. Specifically, these CXC chemokines are translated and produced 
in damaged tissues behind the initial migration of neutrophils [12]. These chemokines 
induce "delayed" dramatic infiltration and activation of neutrophils to promote 
inflammation. 
In this way, various neutrophil-activating factors consisting of bacterial 
N-formylated peptides, complement-derived factors, and CXC chemokines have been 
identified. However, these factors might not be the substances to promote the initial 
migration and activation of neutrophils. Namely, immediate neutrophil migration into 
damaged tissues is observed even in non-infectious tissue injury such as ischemia 
reperfusion injury, trauma and burn. Moreover, it is believed that CXC chemokines 
unable to induce initial infiltration of neutrophils because they are produced 
translationally in injury tissues behind the initial migration of neutrophils [12]. In 
addition, it is controversial whether complement-derived peptides induce neutrophil 
migration by forming a concentration gradient from injury tissues, because 
complement-derived factors are mainly located in bloodstream. Hence, it had been 
unclear what substances induce initial neutrophil migration and activation.  
Mukai and his colleagues therefore attempted to purify such neutrophil-activating 
factors from healthy porcine heart, because immediate and dramatic infiltration of 
neutrophils after ischemia reperfusion injury in the heart causes severe tissue damage. 
They successfully isolated and identified three novel neutrophil-activating peptides 







Figure I-1. Primary structures of MCT-1, MCT-2, and MCT-CYC, and their positions in 





which are derived from mitochondrial cytochrome c oxidase subunit VIII, cytochrome b, 
and cytochrome c, respectively (Figure I-1) [13-15]. They also found the presence of 
many fractions that induced neutrophilic activation other than those containing MCT-1, 
MCT-2, and MCT-CYC, and tried to determine the chemical structures of these 
peptidergic substances in those fractions. Although their complete structures are not yet 
determined, most of those peptides were shown to be fragments of various 
mitochondrial proteins. These observations suggest that neutrophils are regulated by 
many peptides derived from mitochondrial proteins. They therefore named such 
functional cryptic peptides that are hidden in protein structures as ‘‘cryptides’’, and 
those cryptides that are derived from mitochondrial proteins as ‘‘mitocryptides’’[16]. 
After the discovery of mitocryptides, it has been accumulating the evidence that 
indicates the involvement of mitochondria and their derived substances in innate 
immunity. Indeed, various tissues damaged by trauma or burn release mitochondria and 
their contents into bloodstream [17-23]. They are also released from a variety of cells 
damaged by bacterial infection [23-27]. In addition, it is suggested that they are leaked 
into the cerebrospinal fluid from damaged tissues in patients with Alzheimer’s disease 
[28, 29]. These released mitochondria and their derived factors, which are called 
mitochondrial damage-associated molecular patterns (mtDAMPs), promote various 
innate immune responses including induction of neutrophil and macrophage migration 
and activation [17, 19, 23, 30, 31]. MtDAMPs also stimulate the secretion of 
inflammatory mediators from mast cells [32].  
However, it is still unclear what factors in mtDAMPs induce innate immune 
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responses. Namely, mitochondrial DNA (mtDNA) and N-formylated peptides and 
proteins are believed to be activating factors in mtDAMPs. Indeed, it has been shown 
that levels of mtDNA released into the circulation in trauma patients were markedly 
elevated in comparison with healthy volunteers, and the released mtDNA may induce 
sterile inflammation [17]. However, highly purified mtDNA was recently demonstrated 
to be unable to induce neutrophilic responses, thus neutrophilic activation by mtDNA is 
still controversial [33]. On the other hand, although inhibitors against the functions of 
N-formylated peptides partially inhibit the abilities of mtDAMPs [17, 19, 30], 
endogenous N-formylated peptides in mtDAMPs have not been identified yet. Since 
MCT-2 is the only endogenous N-formylated peptide that has been isolated from 
mammalian tissues and its complete chemical structure has been determined, it is a 
leading candidate for activating factors in mtDAMPs. 
As receptors for such N-formylated proteins and peptides including bacterial ones 
as well as MCT-2, formyl peptide receptor 1 (FPR1, formerly referred to as formyl 
peptide receptor) and formyl peptide receptor 2 (FPR2, formerly referred to as formyl 
peptide receptor-like 1) are known to be expressed on the cell membrane of neutrophils 
[34-39]. MCT-2 specifically binds to and activates FPR2, but it neither interacts with 
nor activates FPR1, indicating that MCT-2 is an endogenous specific ligand for FPR2 
[37]. However, the recognition mechanisms of MCT-2 by FPR2 remain unclear. 
In the present study, I therefore investigated the structure–activity relationships of 
MCT-2 and its derivatives to elucidate how FPR2 specifically recognizes MCT-2, and 
showed that the N-terminal heptapeptide structure of MCT-2 with an N-formyl group 
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was the minimum structure that was specifically recognized by FPR2 for its activation. 
Moreover, the receptor for MCT-2 was surprisingly demonstrated to be shifted from 
FPR2 to its homologue FPR1 depending on alterations of its molecular forms, 
suggesting that MCT-2 is a factor that controls not only the initiation of innate immune 
responses against tissue injury but also different responses via the activation of FPR1, 
which may related to resolution and wound healing/tissue regeneration (Chapter II). 
Although MCT-2 was considered to be a first-line candidate as a peptidergic 
activating factor in mtDAMPs, is it the only endogenous N-formylated peptide? It is 
possible that endogenous N-formylated peptides other than MCT-2 are produced and 
activate FPR1 and/or FPR2 to induce innate immune responses including neutrophil 
infiltration and activation, since thirteen proteins are encoded in mitochondrial DNA 
and are translated in mitochondria as N-formylated forms [40, 41]. Thus, I also 
examined the possible existence of endogenous N-formylated peptides other than 
MCT-2 for the induction of innate immune responses. Here I show that several putative 
N-formylated peptides derived from mtDNA-encoded proteins had potencies 
comparable to or higher than MCT-2 in the activation of neutrophilic cells, suggesting 
that endogenous N-formylated peptides other than MCT-2 may also regulate innate 
immune responses (Chapter III). Based on the evidence described in Chapters II and III, 
the innate immune mechanisms involving endogenous N-formylated peptides was 
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Mitocryptides are a novel family of endogenous neutrophil-activating peptides 
originated from various mitochondrial proteins. Mitocryptide-2 (MCT-2) is one of such 
neutrophil-activating peptides and is produced as an N-formylated pentadecapeptide 
from mitochondrial cytochrome b. Although MCT-2 is a specific endogenous ligand for 
formyl-peptide receptor 2 (FPR2), the chemical structure within MCT-2 that is 
responsible for FPR2 activation is still obscure. Here, I demonstrate that the N-terminal 
heptapeptide structure of MCT-2 with an N-formyl group is the minimum structure that 
specifically activates FPR2. Moreover, the receptor molecule for MCT-2 is suggested to 
be shifted from FPR2 to its homolog formyl-peptide receptor 1 (FPR1) by the 
physiological cleavages of its C-terminus. Indeed, N-terminal derivatives of MCT-2 
with 7 amino acid residues or longer than it caused an increase of intracellular free Ca2+ 
concentration in HEK-293 cells expressing FPR2 but not in those expressing FPR1. 
Those MCT-2 derivatives also induced β-hexosaminidase secretion in 
neutrophilic/granulocytic differentiated HL-60 cells via FPR2 activation. In contrast, 
MCT-2(1–4), an N-terminal tetrapeptide of MCT-2, specifically activated FPR1 to 
promote those functions. Moreover, MCT-2 was degraded in serum to produce 
MCT-2(1–4) over time, suggesting that the receptor for MCT-2 was shifted from FPR2 
to FPR1 by its C-terminal cleavage. These findings suggest that MCT-2 is a novel 
critical factor that initiates not only innate immunity via the specific activation of FPR2 
but also promotes delayed responses by the activation of FPR1 which may include 
resolution and tissue regeneration.  
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II-2. Introduction 
Most peptides present in mammals are produced by proteolytic cleavage of 
precursor proteins. That is, functional proteins are first synthesized as precursor proteins, 
which are then cleaved by various processing enzymes to produce mature bioactive 
proteins. After playing their physiological roles, they are inactivated by various 
proteases. During maturation and degradation of these functional proteins, many peptide 
fragments are simultaneously produced. For a long time, these peptide fragments were 
thought to be metabolites without physiological functions.  
However, Mukai and his colleagues found that some of these peptides efficiently 
induce innate immune responses including neutrophil activation. Namely, they have 
identified a novel family of neutrophil-activating peptides including MCT-1, MCT-2, 
and MCT-CYC that endogenously produced from various mitochondrial proteins 
[13-15]. Among them, MCT-2 is an N-formylated pentadecapeptide derived from 
mitochondrial cytochrome b and is found to promote neutrophilic migration and 
phagocytosis efficiently. Signaling mechanisms of neutrophil activation by MCT-2 have 
been investigated at the cellular level, and MCT-2 has been demonstrated to be an 
endogenous specific ligand for FPR2 [37]. In addition, MCT-2 was shown to induce 
neutrophilic functions as a result of Gi2-protein-dependent intracellular signaling events 
including [Ca2+]i increase and ERK1/2 phosphorylation [14, 37]. However, the chemical 
structure within MCT-2 that is specifically recognized by FPR2 is unclear. 
In this chapter, I investigated the structure–activity relationships of MCT-2 and its 
derivatives to elucidate how FPR2 recognizes MCT-2. I also explored the 
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time-dependent alterations of the molecular forms of MCT-2 in serum and attempted to 




II-3. Materials and Methods 
II-3-1. Peptide synthesis 
Human MCT-2 and its derivatives were chemically synthesized by a solid-phase 
method [42-45] using a 9-fluorenylmethyloxycarbonyl strategy [14, 37]. Synthetic 
peptides were purified by reverse phase (RP)-HPLC on a 5C18 column (20 × 250 mm, 
COS-MOSIL; Nacalai Tesque, Inc., Kyoto, Japan). These peptides were analyzed by 
RP-HPLC on a 5C18 column (4.6 × 150 mm, COSMOSIL; Nacalai Tesque, Inc.) and 
were proven to be more than 95% pure (Figure II-1,II-2). The molecular weights of the 
synthesized peptides were also confirmed by MALDI-TOF-mass spectrometry (MS) 
(Table II-1). fMLF was purchased from Nacalai Tesque, Inc. 
 
II-3-2. Preparation of cells 
HEK-293 cells (American Type Culture Collection, Manassas, VA, USA) were 
maintained in DMEM (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% 
FBS (Thermo Fisher Scientific) in a humidified atmosphere at 5% CO2 and 37°C. 
Human acute leukemia-derived HL-60 cells (RIKEN Cell Bank, Ibaraki, Japan) were 
cultured in RPMI-1640 medium (Thermo Fisher Scientific) containing 10% FBS in a 
humidified atmosphere at 5% CO2 and 37 °C. HL-60 cells were treated with 500 µM 
dibutyryl-cAMP (Sigma-Aldrich, St. Louis, MO) for 72 h to differentiate the cells into 








Figure II-1. Analytical RP-HPLC profiles of MCT-2(1–15) (A), MCT-2(1–14) (B), 
MCT-2(1–13) (C), MCT-2(1–12) (D), MCT-2(1–11) (E), MCT-2(1–10) (F), MCT-2(1–
9) (G), MCT-2(1–8) (H), MCT-2(1–7) (I), MCT-2(1–6) (J), MCT-2(1–5) (K), MCT-2(1–
4) (L), and Des-N-formyl MCT-2 (M). Analytical conditions: column, 5C18 column (4.6 
× 150 mm); elution with a linear gradient from 10% to 60% CH3CN/0.1% 
trifluoroacetic acid for 50 min (A–I, K and M) or 0% to 60% CH3CN/0.1% 








Figure II-2. Analytical RP-HPLC profiles of [Ala1]MCT-2 (A), [Ala2]MCT-2 (B), 
[Ala3]MCT-2 (C), [Ala4]MCT-2 (D), [Ala5]MCT-2 (E), [Ala6]MCT-2 (F), [Ala7]MCT-2 
(G), [Ala8]MCT-2 (H), [Ala9]MCT-2 (I), [Ala10]MCT-2 (J), [Ala11]MCT-2 (K), 
[Ala12]MCT-2 (L), [Ala13]MCT-2 (M), [Ala14]MCT-2 (N), and [Ala15]MCT-2 (O). 
Analytical conditions: column, 5C18 column (4.6 × 150 mm); elution with a linear 
gradient from 10% to 60% CH3CN/0.1% trifluoroacetic acid for 50 min; flow rate, 1 











II-3-3. Establishment of HEK-293 cells stably expressing FPR1 or FPR2 
HEK-293 cells stably expressing FPR1 or FPR2 with a Gα16 type of G protein 
were established, as described previously [37]. Briefly, HEK-293 cells were transfected 
with human FPR1/pcDNA3.1/Zeo or human FPR2/pcDNA3.1/Zeo using Lipofectamine 
2000 (Thermo Fisher Scientific). The cells were also co-transfected with 
Gα16/pcDNA3.1/Hygro to induce an agonist-promoted increase in [Ca2+]i. One cell was 
placed into each well of a 96-well plate and selected with 100 µg/mL hygromycin 
(FUJIFILM Wako Pure Chemical, Osaka, Japan) and 250 µg/mL Zeocin (InvivoGen, 
San Diego, CA, USA). Individual cells were further selected by measuring increases in 
[Ca2+]i stimulated by 1 µM fMLF. 
 
II-3-4. Measurement of [Ca2+]i 
The increase in [Ca2+]i stimulated by peptides was assessed, as described 
previously [13, 37]. In brief, HEK-293 cells stably expressing FPR1 or FPR2 with a 
Gα16 type of G protein were washed twice with a HEPES–Na solution (5 mM HEPES, 
140 mM NaCl, 4 mM KCl, 1 mM NaH2PO4, 1 mM MgCl2, 1.25 mM CaCl2, 11 mM 
glucose, and 0.2% BSA, pH 7.4). The Ca2+-sensitive fluorescence reagent 
Fura-2-acetoxymethyl ester (Dojin, Kumamoto, Japan) was added to the cell suspension 
(4 mL; final concentration: 4 µM). The reaction mixture was shielded from light and 
shaken gently at 37 °C for 60 min to load the cells with Fura-2. The cells were 
subsequently washed twice with the HEPES–Na solution and a cell suspension was 
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diluted to a final density of 5.0 × 105 cells/mL. The cell suspension (1 mL) was placed 
into a cuvette and stimulated by peptide solutions (5 µL) with stirring at 37 °C. The 
ratio of fluorescence intensity at 500 nm by excitation wavelengths of 340 nm and 380 
nm was measured using a fluorometer (CAF-100; Japan Spectroscopic Co., Tokyo, 
Japan). 
 
II-3-5. Assay of β-hexosaminidase release 
The ability of MCT-2-related peptides to activate HL-60 cells differentiated into 
neutrophilic/granulocytic cells was evaluated by stimulation of β-hexosaminidase 
secretion from the cells [13-15, 47]. Briefly, differentiated HL-60 cells were washed 3 
times with ice-cold HEPES-buffered Hank’s solution (HBHS; 10 mM HEPES, 136.9 
mM NaCl, 5.4 mM KCl, 1.2 mM CaCl2, 0.44 mM KH2PO4, 0.49 mM MgCl2, 0.41 mM 
MgSO4, 0.34 mM Na2HPO4, 5.5 mM glucose, 4.2 mM NaHCO3, and 0.1% BSA, pH 
7.4). The cells were resuspended in HBHS at a density of 5.6 × 106 cells/mL, and 
DNase I (Sigma-Aldrich) and cytochalasin B (Sigma-Aldrich) were each added at a 
final concentration of 5 µg/mL. The cell suspension in each tube (5.0 × 105 cells/ 90 µL) 
was preincubated at 37 °C for 10 min and stimulated with 10 µL synthetic peptide 
solution at 37 °C for 10 min. The inhibitory effects of inhibitors against FPR1 
[cyclosporin H (CysH)] (Sigma-Aldrich) and FPR2 [PBP10 (Tocris Bio-science, Bristol, 
UK)] on β-hexosaminidase release induced by MCT-2 and its derivatives were also 
evaluated in the differentiated HL-60 cells; each cell suspension prepared as above (90 
µL) was transferred to a tube (5.0 × 105 cells/tube) with 5 µL inhibitor solution for 
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FPR1 (CysH) or FPR2 (PBP10). Each tube was then preincubated at 37 °C for 10 min 
and stimulated with 5 µL synthetic peptide solution at 37 °C for 10 min. After 
stimulation, 200 µL ice-cold reaction quenching buffer (25 mM Tris, 123 mM NaCl, 
and 2.7 mM KCl, pH 7.4) was added to each cell suspension to stop the reaction. 
Thereafter, these tubes were centrifuged at 4 °C and 2300 × g for 1 min, and each 
supernatant was transferred into a new tube. 
β-Hexosaminidase activity in the supernatant was measured as described 
previously [47]. Briefly, 90 µL supernatant was transferred to each well of a 96-well 
microtiter plate, and 60 µL of a substrate solution for β-hexosaminidase [10 mM 
p-nitrophenyl N-acetyl-β-D-glucosaminide (Sigma-Aldrich), 40 mM citrate, and 70 mM 
NaHPO4, pH 4.5] was added to initiate the enzyme reaction. After incubation of the 
plate at 37 °C for 1 h, 100 µL of 400 mM glycine (pH 10.7) was added to stop the 
reaction. The absorbance at 415 nm for the resulting p-nitrophenol and at 490 nm for 
the reference was measured using a microtiter plate reader (Viento XS; BioTek 
Instruments, Winooski, VT, USA). 
The ability of each peptide to induce β-hexosaminidase release was expressed as a 
percentage of enzyme secretion promoted by 10 µM MCT-2(1–15) that induced the 
maximum response for the elucidation of full or partial agonists to the activity of 
MCT-2(1–15) (Figures II-4 and II-6, Table II-2) or a percentage of the total enzyme 
activity, which was the enzyme activity released after disruption of the cells with 0.05% 
Triton X-100 (Figure II-5). 
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II-3-6. Measurement of circular dichroic spectra 
Circular dichroic (CD) spectra of the synthetic peptides were obtained at 25 °C 
using a J-820 spectrometer (Jasco, Tokyo, Japan) in a quartz cell with a 0.1 cm path 
length. Spectra were collected between 190 nm and 250 nm with a scan speed of 50 
nm/min, response time of 1 s, and bandwidth of 1 nm. Peptide samples with a final 
concentration of 100 µM were prepared in 10 mM phosphate buffer (pH 7.4) containing 
0% or 50% TFE. The baseline scan, which was acquired by measuring the buffer alone, 
was subtracted from the experimental readings. CD data, which were collected every 1 
nm, were the average of 5 scans. The results were expressed as the optical rotation 
(mdeg). 
 
II-3-7. Analysis of time-dependent alterations of MCT-2 molecular forms in serum 
The animal experiments were conducted under the guidance of the Animal Care 
and Use Committee of the Nagahama Institute of Bio-Science and Technology 
(Approved No. 047). C57BL/6JJcl mice were purchased from Clea Japan (Tokyo, 
Japan). All mice were maintained in the Animal Research Facility at the Nagahama 
Institute of Bio-Science and Technology. 
Male C57BL/6JJcl mice, 12–14 weeks of age, weighing 25–30 g, were 
anesthetized (50 mg/kg pentobarbital), and blood was collected from the caudal vena 
cava and stored overnight at 4 °C. The blood sample was centrifuged at 4 °C and 20,000 
× g for 20 min, and the supernatant was transferred to a new tube as mouse serum and 
stored at −80 °C. MCT-2 was incubated in mouse serum at a final concentration of 500 
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µM at 37 °C, and aliquots (100 µL) were collected from the incubation mixture after 0, 
1, 2, 4, 24, and 48 h. These aliquots were mixed with TCA (final concentration: 3% 
w/v) and kept on ice for 30 min to precipitate denatured proteins. The samples were 
centrifuged at 4 °C and 13,000 × g for 15 min, and the supernatants were analyzed by 
RP-HPLC on a 5C18 column (4.6 × 150 mm, Cosmosil; Nacalai Tesque, Inc.). 
RP-HPLC peaks that contained MCT-2 and its derivative peptides were analyzed by 
MALDI-TOF-MS to identify their molecular forms. 
 
II-3-8. Statistical Analysis 
Data are expressed as the mean ± standard error (SE) in experiments containing 
multiple data points. Statistical comparisons between two groups were performed using 





II-4-1. Effects of MCT-2(1–15) and its derivatives on [Ca2+]i in HEK-293 cells stably 
expressing FPR1 or FPR2 
An endogenous pentadecapeptide, MCT-2 [MCT-2(1–15)], specifically binds to 
and activates FPR2, but it neither interacts with nor activates FPR1 [37]. In addition, 
MCT-2(1–10) or N-terminal derivatives longer than it specifically activate FPR2 to 
cause β-arrestin recruitment and superoxide production [48]. However, the precise 
structure within MCT-2(1–15) that is responsible for the specific activation of FPR2 is 
not known. Here, increases in the concentration of intracellular free Ca2+ ([Ca2+]i) 
promoted by MCT-2(1–15) and its derivatives were assessed in HEK-293 cells stably 
expressing FPR1 or FPR2 (Figure II-3). The Gα16 type of G protein was also stably 
co-expressed in these cells because this protein interacts with various G protein-coupled 
receptors and effectively induces an agonist-promoted increase of [Ca2+]i [49]. As a 
result, 100 µM MCT-2(1–10), MCT-2(1–9), MCT-2(1–8), and MCT-2(1–7) as well as 
10 µM MCT-2(1–15) induced an increase of [Ca2+]i in HEK-293 cells expressing FPR2, 
but not in FPR1-expressing cells (Figure II-3A–E). In contrast, 100 µM MCT-2(1–5) 
induced an increase of [Ca2+]i in FPR1- and FPR2-expressing cells (Figure II-3F). 
Moreover, 100 µM MCT-2(1–4) promoted an increase of [Ca2+]i in FPR1-expressing 
cells, but not in FPR2-expressing cells (Figure II-3G). In addition, stimulation with 
MCT-2(1–6) did not induce an increase of [Ca2+]i in FPR2- or FPR1-expressing cells, 







Figure II-3. Changes in [Ca2+]i in HEK-293 cells stably expressing FPR1 (formyl 
peptide receptor 1) or FPR2 (formyl peptide receptor 2) induced by MCT-2 
(Mitocryptide-2)(1–15) and its derivatives. Fura-2-loaded cells were stimulated with 10 
µM MCT-2(1–15) (A) or 100 µM MCT-2(1–10) (B), MCT-2(1–9) (C), MCT-2(1–8) (D), 
MCT-2(1–7) (E), MCT-2(1–5) (F), and MCT-2(1–4) (G). The changes in the 
fluorescence ratio of Fura-2 (excitation wavelengths, 340 nm and 380 nm; emission 
wavelength, 500 nm) were recorded by a fluorometer CAF-100. Horizontal axes show 
the times after stimulation. Vertical axes depict the fluorescence ratios at excitation 






N-terminal derivative MCT-2(1–7) and its longer derivatives specifically activate FPR2, 
in contrast with MCT-2(1–4), which specifically activates FPR1. 
 
II-4-2. Effects of C- or N-terminal truncations of MCT-2(1–15) on β-hexosaminidase 
release from neutrophilic/granulocytic differentiated HL-60 Cells 
The effects of N- or C-terminal truncations of MCT-2 on β-hexosaminidase 
released from neutrophilic/granulocytic differentiated HL-60 cells were investigated to 
elucidate the minimum structure that was required for the activation of their receptor 
molecules. As our research group reported previously [14], a pentadecapeptide MCT-2 
[MCT-2(1–15)] dose-dependently promoted β-hexosaminidase secretion from 
differentiated HL-60 cells (EC50: 20 ± 3 nM, Figure II-4 and Table II-2), and the 
maximum response was observed at concentrations greater than 1 µM. 
To elucidate the necessity of the N-formyl group for this stimulation, I examined the 
effects of its removal from MCT-2(1–15). Des-N-formyl MCT-2(1–15) did not induce 
β-hexosaminidase release, even at a concentration of 100 µM (Figure II-4A), 
demonstrating that the formyl group at the N-terminus of MCT-2(1–15) is crucial for 
this process. 
Next, I examined the importance of the C-terminal sequence of MCT-2(1–15) for 
the stimulation of β-hexosaminidase release from differentiated HL-60 cells by 







Figure II-4. Effects of N- or C-terminal truncations of MCT-2(1–15) on 
β-hexosaminidase release by differentiated HL-60 cells. The differentiated HL-60 cells 
were stimulated by MCT-2(1–15) or its derivatives at 37 °C for 10 min, and the amount 
of the released β-hexosaminidase was quantified as described in “Materials and 
Methods”. The ability of each peptide to induce β-hexosaminidase release is expressed 
as a percentage of enzyme secretion promoted by 10 µM MCT-2(1–15). Data are 





Table II-2. Amino acid sequences and experimental data for MCT-2(1–15) and its 
derivatives and their EC50 values and maximum effects on the induction of 
β-hexosaminidase release from differentiated HL-60 cells. 
 
 
aThe ability of each peptide to cause β-hexosaminidase release is expressed as a 
percentage of enzyme secretion promoted by 10 µM MCT-2(1–15). Data are expressed 
as the mean ± SE of four to six independent experiments. ** p < 0.01; *** p < 0.001, 






from the C-terminus of MCT-2(1–15) caused consecutive increases in the EC50 values 
without affecting the maximum response. Specifically, the EC50 value of MCT-2(1–14) 
was increased by approximately fivefold compared with that of MCT-2(1–15) (Figure 
II-4B and Table II-2). MCT-2(1–13) and MCT-2(1–12) also exhibited decreased activity 
when compared with MCT-2(1–15), but MCT-2(1–11) had almost the same potency as 
MCT-2(1–12) (Figure II-4B and Table II-2). In addition, the activities of MCT-2(1–10), 
MCT-2(1–9), and MCT-2(1–8) were sequentially attenuated compared with that of 
MCT-2(1–11), but with the same maximum effect as MCT-2(1–15), and MCT-2(1–7) 
had almost the same potency as MCT-2(1–8). However, MCT-2(1–6), a derivative that 
was truncated by nine C-terminal amino acid residues, exhibited a significant decrease 
of the maximum response compared with MCT-2(1–15) (maximum response: 90 ± 3%) 
with a 5.7-fold increase in the EC50 value compared with MCT-2(1–7). These results 
indicate that MCT-2(1–7) with an N-formyl group is the minimum structure that is 
required for maximum stimulation via the activation of FPR2 because the minimum 
sequence that gave the same level of maximum response as MCT-2(1–15) was 
MCT-2(1–7), which was also the minimum structure for inducing specific FPR2 
activation to cause an increase of [Ca2+]i (Figure II-3). In addition, the MCT-2(8–15) 
structure within MCT-2(1–15) may contribute to the binding affinity between 
MCT-2(1–15) and FPR2, since the removal of one to eight amino acid residues from the 
C-terminus did not affect the maximum response, but caused a consecutive increase in 
EC50 values (Figure II-4B and Table II-2). 
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The effect of C-terminal truncation was examined further because MCT-2(1–6) 
could still induce β-hexosaminidase release. As a result, MCT-2(1–5), surprisingly, had 
6.5-fold higher activity than MCT-2(1–6) (Figure II-4C and Table II-2) with the same 
level of maximum response as MCT-2(1–15). Moreover, the activity of MCT-2(1–4) 
was further reinforced compared with MCT-2(1–5) as well as MCT-2(1–6) (Table II-2); 
nevertheless, the maximum response of MCT-2(1–4) was significantly reduced by 
approximately 10% compared with MCT-2(1–15). Taken together with the observations 
that MCT-2(1–5) induced the activation of FPR2 and FPR1, and MCT-2(1–4) 
specifically activated FPR1 for the increases in [Ca2+]i described above (Figure II-3), 
these findings suggest that MCT-2(1–5) effectively promotes the stimulation of 
β-hexosaminidase release via FPR1 and FPR2 activation. Furthermore, MCT-2(1–4) 
specifically activates FPR1 to promote stimulation. 
 
II-4-3. Involvement of FPR1 and FPR2 in β-hexosaminidase release stimulated by 
MCT-2(1–15) and its derivatives 
To further elucidate the involvement of FPR1 and FPR2 in β-hexosaminidase 
release from differentiated HL-60 cells stimulated with MCT-2(1–15) and its derivatives, 
I examined the inhibitory effects of inhibitors against FPR1 [cyclosporin H (CysH)] and 
FPR2 (PBP10) on this process. Stimulation with MCT-2(1–15) at 40 nM, which induced 
approximately 60% of the maximum response, was dose-dependently inhibited by 






Figure II-5. Involvement of FPR1 and FPR2 in β-hexosaminidase release by 
differentiated HL-60 cells stimulated with MCT-2(1–15) and its derivatives. (A,B) 
Concentration-dependent inhibitory effects of inhibitors against FPR1 (CysH) (A) or 
FPR2 (PBP10) (B) on β-hexosaminidase release induced by MCT-2(1–15) and its 
derivatives. (C) Inhibitory effects of CysH (1 µM; black), PBP10 (1 µM; gray), or a 
combination of both inhibitors (1 µM PBP10 and 1 µM CysH; slash lines) on the 
stimulation of β-hexosaminidase release by MCT-2(1–15) and its derivatives. White 
bars indicate the stimulation of MCT-2(1–15) and its derivatives in the absence of the 
inhibitor. The stimulatory concentrations of MCT-2(1–15) and its derivatives were the 
concentrations that caused a 60% response of the maximum effect. The ability of each 
peptide in the absence or the presence of the inhibitors was expressed as a percentage of 
the total enzyme activity, which was the enzyme activity leaked after disruption of the 
cells with 0.05% Triton X-100 (%/Total). Data are expressed as the mean ± SE of four 
to six independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001, values 
significantly different from each peptide in the absence of the inhibitors. (D) Receptor 
preference of MCT-2(1–15) and its derivatives. N-terminal derivatives of MCT-2 with 
seven amino acid residues [MCT-2(1–7)] or longer than it specifically activate FPR2, 
whereas MCT-2(1–4) induces the specific activation of FPR1, as well as MCT-2(1–6) 




influence MCT-2(1–15)-induced enzyme release (Figure II-5A,B). Similarly, the 
responses induced by MCT-2(1–10), MCT-2(1–9), MCT-2(1–8), and MCT-2(1–7) at a 
concentration that caused a 60% response of the maximum effect were also abolished in 
a dose-dependent manner by PBP10 but not CysH (Figure II-5A,B). In contrast, 
stimulation with MCT-2(1–6) and MCT-2(1–5) was almost completely prevented by the 
combination of inhibitors (1 µM CysH and 1 µM PBP10) (Figure II-5C). Moreover, 
β-hexosaminidase release induced by MCT-2(1–4) was completely abolished by 1 µM 
CysH, but was unaffected by 1 µM PBP10 (Figure II-5A,B). These results also support 
the notion that MCT-2(1–7) and its longer N-terminal derivatives induce 
β-hexosaminidase release from differentiated HL-60 cells via the specific activation of 
FPR2; in contrast, MCT-2(1–4) specifically activates FPR1, and MCT-2(1–6) and 
MCT-2(1–5) activate both FPR1 and FPR2 (Figure II-5D). 
 
II-4-4. Effects of substituting Ala for each amino acid residue of MCT-2(1–15) on 
β-hexosaminidase release by differentiated HL-60 cells 
I examined the effect of substituting Ala for each amino acid residue in MCT-2(1–
15) on the stimulation of β-hexosaminidase release to elucidate the contribution of each 
side chain structure to this process. As the MCT-2(1–7) structure with an N-formyl 
group was indicated as crucial for the activation of FPR2 (Figures II-3–5), I investigated 
the effect of substituting Ala for each amino acid residue in positions one to seven 
within MCT-2(1–15). The replacement of Met1 of MCT-2(1–15) with Ala caused a 30% 
 34 
reduction of the maximum response with a dramatic (>500-fold) increase in the EC50 
value compared with MCT-2(1–15) (Figure II-6A and Table II-2), indicating that the 
Met1 side chain is important for not only the affinity of MCT-2(1–15) to FPR2, but also 
for FPR2 activation. The substitution of Met4, Arg5, Lys6, or Ile7 with Ala also caused an 
increase in the EC50 value with the same level of maximum response as MCT-2(1–15). 
In contrast, the replacement of Thr2 with Ala promoted a remarkable decrease in the 
EC50 value without affecting the maximum response, although the substitution of Pro3 
with Ala had no effect on the EC50 value. These results suggest that the side chains of 
Met4, Arg5, Lys6, and Ile7, and Thr2 within MCT-2(1–15) contribute positively and 
negatively, respectively, to its affinity to bind to FPR2. 
I also examined the effect of substituting Ala for each amino acid residue in the 
MCT-2(8–15) sequence within MCT-2(1–15) because this structure may be important 
for the binding affinity between MCT-2(1–15) and FPR2, but not the receptor activation 
described above. The substitution of Leu10, Leu13, or Ile14 with Ala caused an increase in 
the EC50 value with the same level of maximum response as MCT-2(1–15) (Figure 
II-6B and Table II-2). In contrast, the replacement of Pro9 with Ala promoted a 
remarkable decrease in the EC50 value without affecting the maximum response [EC50: 
3 ± 2 nM, Figure II-6B and Table II-2], although the substitution of Asn8, Met11, Lys12, 
or Asn15 with Ala had no effect. These results suggest that the Leu10, Leu13, or Ile14, and 







Figure II-6. Effects of substituting Ala for each amino acid residue of MCT-2(1–15) on 
β-hexosaminidase release by differentiated HL-60 cells. The differentiated HL-60 cells 
were stim-ulated by MCT-2(1–15) or its derivatives at 37 °C for 10 min, and the amount 
of the released β-hexosaminidase was quantified as described in “Materials and 
Methods”. The ability of each peptide to cause β-hexosaminidase release is expressed as 
a percentage of enzyme secretion promoted by 10 µM MCT-2(1–15). Data are 







to its affinity to bind to FPR2. 
 
II-4-5. Circular dichroic spectra of MCT-2(1–15) and its derivatives 
It was suggested that the Thr2, Met4, Arg5, Lys6, Ile7, Pro9, Leu10, Leu13, and Ile14 
side chains within MCT-2(1–15) had an effect on its binding affinity to FPR2 and that 
the MCT-2(8–15) structure was important for binding to FPR2. Thus, the secondary 
structures of MCT-2(1–15) and its derivatives were analyzed using CD spectra, which is 
an excellent tool for the rapid investigation of secondary structures. As described 
previously [48], the CD spectrum of MCT-2(1–15) exhibited two minima at 225 nm and 
205 nm in TFE solution, suggesting that MCT-2(1–15) predominantly contained an 
α-helical structure in hydrophilic circumstance (Figure II-7A). Similarly, the spectra of 
the N-terminal MCT-2 derivatives that were truncated by one to six amino acid residues 
from the C-terminus of MCT-2(1–15) at 100 µM also showed two minima at 225 nm 
and 202–208 nm in TFE solution, although these minima were consecutively attenuated 
by the C-terminal truncations (Figure II-7B–G). Moreover, the spectra of MCT-2(1–8) 
and MCT-2(1–7) displayed a minimum at approximately 200 nm in TFE solution 
(Figure II-7H,I), proposing that MCT-2(1–8) and MCT-2(1–7) do not contain defined 
secondary structures, even under hydrophilic conditions. In contrast, the CD spectra of 
all of these derivatives including MCT-2(1–15) at 100 µM exhibited a minimum at 







Figure II-7. CD spectra of MCT-2(1–15) and its derivatives. The CD spectra of 
MCT-2(1–15) (A), MCT-2(1–14) (B), MCT-2(1–13) (C), MCT-2(1–12) (D), MCT-2(1–
11) (E), MCT-2(1–10) (F), MCT-2(1–9) (G), MCT-2(1–8) (H), and MCT-2(1–7) (I) in 
50% TFE buffer (solid lines) or 10 mM phosphate buffer (pH 7.4) (dashed lines) were 
measured with a CD spectrometer. CD data with peptide solutions (final concentration: 
100 µM) were the average of five scans collected at 1 nm intervals. The results are 






MCT-2(1–15) and its derivatives did not form defined secondary structures in 
hydrophilic conditions. 
 
II-4-6. Time-dependent alterations of the molecular forms of MCT-2(1–15) in serum 
I examined the alterations of the molecular forms of MCT-2(1–15) in serum to 
elucidate the time-dependent degradation of MCT-2(1–15). MCT-2(1–15) was 
incubated with mouse serum, and the production of MCT-2-derived peptides was 
analyzed by RP-HPLC. The molecular masses of the newly produced peaks were 
measured by MALDI-TOF-MS to identify the molecular forms of the MCT-2-related 
peptides. As a result, the amount of MCT-2(1–15) in serum was reduced by 
approximately 50% and 80% at 1 and 2 h after incubation, respectively, and MCT-2(1–
15) completely disappeared at 4 h (Figure II-8), indicating that its half-life in serum was 
approximately 1 h. In contrast, MCT-2(1–11), MCT-2(1–10), and MCT-2(1–4) were 
produced simultaneously with the decrease in the amount of MCT-2(1–15), that is, the 
production of MCT-2(1–11) and MCT-2(1–10) was detected at 1 h, and the maximum 
amounts of MCT-2(1–11) and MCT-2(1–10) were observed at 1 and 2 h after incubation, 
respectively (Figure II-8B,C). MCT-2(1–11) and MCT-2(1–10) were not found at 4 h 
after incubation (Figure II-8D). MCT-2(1–4) was detected initially at 1 h after 
incubation but at a low level, and its maximum level was observed at 4 h (Figure II-8B–








Figure II-8. Time-dependent alteration of the molecular forms of MCT-2(1–15) in serum. 
The alteration of the molecular forms of MCT-2(1–15) in serum was examined as 
described in the Materials and Methods. Briefly, MCT-2(1–15) was incubated in mouse 
serum at 37 °C for 0, 1, 2, 4, 24, and 48 h, and samples at those time points were 
analyzed by RP-HPLC. The panels show the analytical RP-HPLC profile of each 
sample at 0 (A), 1 (B), 2 (C), 4 (D), 24 (E), or 48 (F) h after incubation. Black and red 
lines indicate the samples that were incubated with and without MCT-2(1–15), 
respectively. Analytical conditions: column, 5C18 column (4.6 × 150 mm); elution with 
a linear gradient from 10% to 60% CH3CN/0.1% trifluoroacetic acid for 50 min; flow 
rate, 1 mL/min; detection wavelength, 214 nm. The arrows indicate the peaks 







present at 48 h (Figure II-8F). In addition, no fragmented peptides derived from 
MCT-2(1–15) were observed at any time point. These results suggest that MCT-2(1–15) 
is degraded by various proteases in serum, and MCT-2(1–11), MCT-2(1–10), and 
MCT-2(1–4) are produced simultaneously. Moreover, it is considered that MCT-2(1–4) 
may be produced by the degradation of MCT-2(1–15), MCT-2(1–11), or MCT-2(1–10), 
and was present in serum for more than 48 h. These findings suggest that MCT-2(1–15) 






II-5-1. Recognition mechanisms of MCT-2(1–15) and its derivatives by formyl-peptide 
receptors 
FPR1, which recognizes N-formylated peptides, and its homolog FPR2 are 
expressed in neutrophils and neutrophilic differentiated HL-60 cells [34-36, 39, 46, 
50-52], and the endogenous pentadecapeptide MCT-2(1–15) specifically activates FPR2 
but not FPR1 (37, 49; see also Figures II-3–6). At first, I examined the structure–
activity relationships of MCT-2(1–15) to identify the minimum structure that is required 
for specific FPR2 acti-vation. I found that the N-formyl group of MCT-2(1–15) was 
crucial for the induction of β-hexosaminidase release stimulated by the peptide, and 
suggested that the Met1 side chain contributed not only to the affinity of MCT-2(1–15) 
to bind to FPR2 but also to receptor activation (Figures II-3–6). 
I also showed that MCT-2(1–4), which is an N-terminal tetrapeptide of MCT-2(1–
15), induced β-hexosaminidase release, but surprisingly, MCT-2(1–4) specifically 
activated FPR1 (Figures II-3–5). Specifically, the evidence that MCT-2(1–4) promoted 
an increase of [Ca2+]i in HEK-293 cells expressing FPR1 but not in those expressing 
FPR2, as well as the evidence that its stimulation for β-hexosaminidase secretion was 
specifically inhibited by the FPR1 inhibitor CysH but not FPR2 inhibitor PBP10 
indicates that MCT-2(1–4) induces β-hexosaminidase secretion in differentiated HL-60 
cells via the specific activation of FPR1. In addition, MCT-2(1–5), a derivative that was 
extended by C-terminal 1 amino acid residue to MCT-2(1–4), also exhibited the 
induction of β-hexosaminidase release (Figure 2C), but in contrast with MCT-2(1–4), 
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MCT-2(1–5) caused an increase of [Ca2+]i in both FPR1- and FPR2-expressing 
HEK-293 cells (Figure II-3F,G). These findings suggest that MCT-2(1–5) promotes 
β-hexosaminidase secretion via the activation of FPR1 and FPR2. The idea that 
MCT-2(1–5) activates FPR1 and FPR2 to induce β-hexosaminidase secretion was also 
supported by the use of selective inhibitors against FPR1 and FPR2; the stimulation of 
MCT-2(1–5) was partially inhibited by CysH or PBP10 and was completely prevented 
by a combination of both inhibitors (Figure II-5C). 
In contrast with MCT-2(1–4) and MCT-2(1–5), MCT-2(1–7) induced 
β-hexosaminidase release via the specific activation of FPR2. Indeed, MCT-2(1–7) 
promoted β-hexosaminidase secretion in differentiated HL-60 cells and caused an 
increase of [Ca2+]i in HEK-293 cells expressing FPR2 but not in those expressing FPR1 
(Figures II-3E and II-4B). MCT-2(1–7) was also demonstrated to be a full agonist for 
FPR2 because the maximum response of MCT-2(1–7) to potentiate β-hexosaminidase 
secretion was at the same level as that induced by MCT-2(1–15), an endogenous 
specific agonist for FPR2. Moreover, N-terminal derivatives longer than MCT-2(1–7) 
also exhibited the same maximum effect as MCT-2(1–15) on the stimulation of 
β-hexosaminidase release, and those EC50 values were simultaneously reduced by 
C-terminal extension, that is, the activity of the derivatives was consecutively 
potentiated (Figure II-4B). In addition, similar to MCT-2(1–7), the N-terminal 
derivatives MCT-2(1–8), MCT-2(1–9), and MCT-2(1–10) as well as MCT-2(1–15) 
caused an increase of [Ca2+]i only in HEK-293 cells expressing FPR2 (Figure II-3A–E). 
These findings indicate that the N-terminal derivatives longer than MCT-2(1–7) are also 
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specific full agonists for FPR2 to promote β-hexosaminidase secretion. This notion 
concerning the receptor preference of MCT-2(1–15) and its derivatives was also 
supported by experiments using selective inhibitors against FPR1 and FPR2. 
Specifically, the stimulation of β-hexosaminidase release by MCT-2(1–7) and its longer 
N-terminal derivatives was completely inhibited by the FPR2 inhibitor PBP10, but was 
unaffected by the FPR1 inhibitor CysH (Figure II-5A,B). 
MCT-2(1–6) did not induce an increase of [Ca2+]i in HEK-293 cells expressing 
either FPR2 or FPR1, even at 100 µM; nevertheless, it caused β-hexosaminidase 
secretion (Figure II-4). The apparent discrepancy between the induction of 
β-hexosaminidase release and increase in [Ca2+]i stimulated by MCT-2(1–6) may be a 
result of its weak stimulatory activity for not only FPR1, but also FPR2; the weak 
stimulation of β-hexosaminidase release by MCT-2(1–6) was presumably a 
consequence of the slight activation of both FPR1 and FPR2, although this was not 
evident in HEK-293 cells expressing FPR1 or FPR2. The idea that MCT-2(1–6) weakly 
activates FPR1 and FPR2 for the induction of β-hexosaminidase secretion was also 
supported by the use of selective inhibitors against FPR1 or FPR2, i.e., 
β-hexosaminidase release stimulated by MCT-2(1–6) was partially inhibited by either 






II-5-2. Secondary structures of MCT-2(1–15) and its derivatives for the interaction 
with FPR2 
In the present study, I showed that the MCT-2(1–7) structure within MCT-2(1–15) 
is required to induce the maximum response by FPR2 activation. What is the role of the 
C-terminal MCT-2(8–15) sequence within MCT-2(1–15)? Truncation of one to eight 
amino acid residues from the C-terminus of MCT-2(1–15) had no effect on the 
maximum response for the stimulation of β-hexosaminidase release, but did cause a 
consecutive increase of EC50 values (Figure II-4B and Table II-2), suggesting that the 
MCT-2(8–15) structure contributes to the binding affinity of MCT-2(1–15) to FPR2, but 
is not essential for the receptor activation itself. Especially, the removal of the Ile14, 
Leu13, Met11, and Leu10 side chains from MCT-2(1–15) significantly increased the EC50 
values, suggesting that these hydrophobic amino acid residues are important for the 
affinity of MCT-2(1–15) with FPR2. Many bioactive peptides form amphipathic 
α-helical structures when interacting with the cell membrane, and the hydrophobic side 
chains of those peptides influence their affinity for the cell membrane and their 
receptors [53, 54]. Indeed, MCT-2(1–15) exhibited α-helical signals in CD spectra in 
hydrophilic conditions, and the truncation of one to eight amino acid residues from its 
C-terminus caused a simultaneous decrease of the α-helical signals (Figure II-7). These 
findings propose that the α-helical structure of MCT-2(1–15) formed in hydrophilic 
circumstance may also contribute to its interaction with FPR2. Here, the substitution of 
Pro9 in MCT-2(1–15) with Ala remarkably decreased the EC50 value for 
β-hexosaminidase release, i.e., its activity was potentiated by the exchange (Figure 
 45 
II-6B). Taken together with our previous findings that the replacement of Pro9 in 
MCT-2(1–15) with Ala increased the α-helical content in hydrophilic conditions [48], 
the importance of the amphiphilic α-helical structure of the C-terminal part of 
MCT-2(1–15) for the improvement of its affinity for FPR2 was also supported by these 
results. 
In this study, the Thr2 side chain was also suggested to contribute negatively to the 
affinity of MCT-2(1–15) for FPR2, that is, the replacement of Thr2 in MCT-2(1–15) 
with Ala promoted a remarkable decrease in the EC50 value (Table 2); nevertheless, this 
substitution did not influence the α-helical content of MCT-2(1–15) [48]. Hence, the 
increase in activity by its replacement may be a result of an increase in hydrophobicity 
at position two that improves its binding affinity with FPR2. 
 
II-5-3. Binding characteristics of MCT-2(1–15) and its derivatives to FPR1 and FPR2 
Recently, the tertiary structure of the FPR2-Gi complex analyzed by cryo-electron 
microscopy (EM) has been reported, and that of the FPR1-Gi complex was also 
predicted based on the structure of FPR2 by Zhuang et al. [55]. In addition, formylated 
peptides containing fMLF were docked to those receptors. These findings suggested 
that the N-formyl groups of those peptides interacted with the Asp106, Arg201, and Arg205 
residues distributed at the bottom of the ligand-binding cavities of FPR1 and FPR2 for 
the activation of both receptors. Thus, I simulated the docking of MCT-2(1–15) and its 
derivatives to FPR2 and FPR1 using the Glide program in Schrödinger, which was the  
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program used by Zhuang et al. [55] (Figure II-9). In brief, the N-formyl group of 
MCT-2(1–15) and its N-terminal derivatives longer than seven amino acid residues were 
also shown to interact with Asp106, Arg201, and Arg205 of FPR2 but not those of FPR1 
because these peptides caused steric hindrance on binding to the cavity of FPR1 (Figure 
II-9A and C vs. Figure II-9E,G). Moreover, the Met1 side chains of those peptides filled 
the space at the bottom of the ligand-binding cavity of FPR2 (Figure II-9A,C), 
presumably contributing to the stabilization of the interaction between the N-formyl 
groups of those peptides and Asp106, Arg201, and Arg205 of FPR2 for receptor activation. 
In contrast, MCT-2(1–4) just fit into the binding cavity of FPR1 to promote the 
interaction between its N-formyl group and Asp106, Arg201, and Arg205 (Figure II-9F,H). 
However, the interaction between MCT-2(1–4) and the ligand-binding cavity of FPR2 
was not stabilized due to the lack of hydrophobic and hydrogen bonding interactions as 
well as the large binding cavity (Figure II-9B,D) (docking score: FPR1–MCT-2(1–4) 
model, -4.84 vs. FPR2–MCT-2(1–4) model, -3.84). 
In addition, the Arg5 or Lys6 residue of MCT-2(1–7) and the C-terminal carboxyl 
group of MCT-2(1–4) were exhibited to form hydrogen bonds with the Asp281 residue of 
FPR2 and the Arg84 residue of FPR1 (Figure 7C,H), respectively, which are distributed 
at the top of the binding cavities of those receptors, proposing that these hydrogen 
bonding interactions are of importance for stabilizing further receptor–peptide binding. 






Figure II-9. Molecular docking of MCT-2(1–7) and MCT-2(1–4) to FPR2 or FPR1. 
MCT-2(1–7) and MCT-2(1–4) are shown as green sticks and orange sticks, respectively. 
(A,B) The docking model of MCT-2(1–7) (A) and MCT-2(1–4) (B) to FPR2. (C,D) 
Detail of the ligand-binding cavity of FPR2. The structure of the ligand-binding cavity 
of FPR2 is shown in blue. (E,F) The docking model of MCT-2(1–7) (E) and MCT-2(1–
4) (F) to FPR1. (G,H) Detail of the ligand-binding cavity of FPR1. The structure of the 
ligand-binding cavity of FPR1 is shown in yellow. Hydrogen bonding interactions are 




the peptides in the present study in which MCT-2(1–7) and its derivatives longer than 
seven amino acid residues specifically activated FPR2, whereas MCT-2(1–4) 
specifically activated FPR1. 
 
II-5-4. Alteration of the molecular forms of MCT-2(1–15) in the bloodstream 
Since the receptor preference of MCT-2(1–15) and its derivatives critically 
depends on the length of its C-terminus, changes in the molecular forms of MCT-2(1–
15) in serum were investigated. MCT-2(1–15) in serum was detected within 4 h after 
incubation, and its half-life was approximately 1 h (Figure II-8). In addition, the 
production of MCT-2-related FPR2 specific agonists MCT-2(1–11) and MCT-2(1–10) 
was observed at 1 h after incubation, but they were no longer present at 4 h, similar to 
MCT-2(1–15) (Figure II-8). Since MCT-2(1–15) is proposed to be released into the 
bloodstream from injury tissues as discussed below, these results suggest that MCT-2(1–
15) released into the bloodstream initially activates FPR2 for several hours. In contrast, 
the MCT-2-related FPR1 specific agonist MCT-2(1–4) was found at low levels at 1 h 
after incubation; its levels then increased gradually over time, and its maximum amount 
was observed at 4 h. Moreover, MCT-2(1–4) was still present at 48 h (Figure II-8). 
These findings propose that MCT-2(1–15) released into the bloodstream is degraded 
and the resulting product, MCT-2(1–4), induces the activation of FPR1 following FPR2 




II-5-5. Possible physiological roles of the receptor preference shift of MCT-2(1–15) 
from FPR2 to FPR1 
The results of this study demonstrate that the receptor preference of MCT-2(1–15) 
is shifted from FPR2 to FPR1 by the cleavage of its C-terminus. What is the 
physiological significance of this shift in receptor preference? 
FPR1 and FPR2 play critical roles in inflammation including proinflammatory 
responses, subsequent resolution, and wound healing/tissue regeneration. Specifically, 
FPR1 and FPR2 are expressed mainly by inflammatory immune cells including 
neutrophils, monocytes, and monocyte-derived macrophage cells such as tissue-resident 
macrophages and microglia [36, 38, 39], and FPR2 is also expressed by a variety of 
cells including microvascular endothelial cells [39, 56]. FPR1 and FPR2 have roles in 
the mechanisms concerning the infiltration of neutrophils and macrophages into injury 
sites, and their activation causes various inflammatory responses, including 
phagocytosis, superoxide generation, and inflammatory cytokine production [36, 38, 39]. 
In addition, there is evidence indicating that the activation of FPR2 increases the 
vascular permeability of endothelial cells [39, 56], suggesting a further promotion of 
neutrophil infiltration from the bloodstream into injury sites following receptor 
activation in the initial stage of inflammation. Thus, the activation of FPR1 and FPR2 
expressed by neutrophils, macrophages, and endothelial cells induces various innate 
immune responses initiated by the infiltration and activation of neutrophils. Oppositely, 
it is known that liganded FPR2 suppresses the production of inflammatory cytokines 
following the acute proinflammatory responses [39, 57-60]. Moreover, FPR1 activation 
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has been demonstrated to promote wound healing/tissue regeneration, including cell 
proliferation [12, 61-65]. 
It is believed that mitochondrial-derived N-formylated peptides activate FPR1 and 
FPR2 as endogenous activating factors. Indeed, mtDAMPs consisting of mitochondria 
and their contents are released into the bloodstream as a result of sterile tissue damage 
such as trauma [17-23], and still unidentified endogenous N-formylated peptides in 
mtDAMPs are thought to activate FPR1 and/or FPR2 to induce innate immune 
responses [17, 19, 30]. MCT-2(1–15) is the only endogenous N-formylated peptide 
whose chemical structure has been determined so far, and the presence of 
MCT-2-related peptides in mtDAMPs was recently observed by immunoblot analysis 
using a monoclonal antibody against MCT-2. Taken together with these findings, the 
present results suggest the hypothesis that MCT-2(1–15) is initially released into the 
bloodstream from damaged cells following tissue injury, and then activates FPR2 
specifically to induce acute innate immune responses, including the infiltration and 
activation of neutrophils. MCT-2(1–15) is then degraded in damaged tissues as well as 
in the bloodstream over time, and the resulting MCT-2-related FPR1 specific agonist 
MCT-2(1–4) activates FPR1 to promote delayed responses, which may include 
resolution and wound healing/tissue regeneration (Figure II-10). Indeed, we recently 
found that a specific neutralizing monoclonal antibody against MCT-2 attenuated the 
infiltration of neutrophils into injured liver tissue in acetaminophen- or LPS-induced 







Figure II-10. Proposed mechanisms of innate immune responses involving MCT-2(1–
15). MCT-2(1–15) released from damaged cells firstly activates FPR2 to induce 
proinflammatory responses. Released MCT-2(1–15) is then degraded over time to 
produce MCT-2(1–4), and the resultant MCT-2(1–4) activates FPR1 to promote delayed 
responses, which may be related to resolution and wound healing/tissue regeneration. 






derivatives play a critical role in innate immunity. The present findings also indicate the 
crucial importance of investigating the molecular forms and/or exact chemical 
structures of those activating factors to elucidate the mechanisms underlying innate 
immune responses. 
In conclusion, I demonstrated that FPR2 recognizes the MCT-2(1–7) structure 
with an N-formyl group for its specific activation to induce neutrophilic functions.  
N-terminal MCT-2 derivatives shorter than seven amino acid residues were shown to 
lose their specificity for FPR2 and gain the ability to activate FPR1. Moreover, I 
showed that MCT-2(1–15) was degraded in serum over time, and the MCT-2-related 
FPR1 specific agonist MCT-2(1–4) was produced, suggesting that the receptor 
preference of MCT-2(1–15) in the bloodstream is shifted from FPR2 to FPR1 over time 
by the cleavage of its C-terminus by various proteases. Thus, MCT-2 is proposed to be a 
factor that controls not only the initiation of innate immune responses against tissue 
injury, but also delayed responses via the activation of FPR1, which may relate to 
resolution and wound healing/tissue regeneration. In addition, because the docking 
simulation of MCT-2(1–15) and its derivatives to FPR1 or FPR2 well explained the 
receptor-specific activation mechanisms by those peptides as well as the results of 
structure–activity relationships, the present findings with structural information of FPR2 
and FPR1 are expected to accelerate the development of specific antagonists for not 
only FPR2 but also FPR1 for the treatment of various inflammatory diseases including 

















It is known that thirteen proteins encoded in mitochondrial DNA are translated in 
mitochondria as N-formylated forms, proposing the existence of endogenous 
N-formylated peptides other than mitocryptide-2 (MCT-2). Here I investigated the 
effects of N-formylated peptides presumably cleaved from mitochondrial DNA-encoded 
proteins other than cytochrome b on the functions of neutrophilic cells in order to 
elucidate physiological regulations by endogenous N-formylated peptides in innate 
immunity. Four N-formylated peptides derived from cytochrome c oxidase subunit I and 
NADH dehydrogenase subunits 4, 5, and 6 among twelve peptides derived from 
mitochondrial DNA-encoded proteins efficiently induced not only migration but also 
β-hexosaminidase release, which is an indicator of phagocytosis in HL-60 cells 
differentiated into neutrophilic cells with the activities that were comparable to or 
higher than those induced by MCT-2. These findings suggest that not only MCT-2 but 
also those N-formylated peprides presumably cleaved from mtDNA-encoded proteins 





Recently, mitochondrial damage-associated molecular patterns (mtDAMPs) are 
paid much attention as pro-inflammatory factors in sterile inflammation that were 
caused by internal tissue damages including ischemic injuries/infarction, trauma, and 
burn [17-23]. mtDAMPs are demonstrated to be released from those tissue injury sites, 
and are shown to induce neutrophil migration and activation. One family of activating 
factors contained in mtDAMPs is believed to be endogenous N-formylated peptides, 
although they have not been molecularly specified yet. It is considered that MCT-2 is a 
first-line candidate as a peptidergic activating factor in mtDAMPs, since it is an only 
endogenous neutrophil-activating N-formylated peptide that has been isolated and 
identified from mammalian tissues so far [14]. Moreover, endogenous N-formylated 
peptides other than MCT-2 possibly exist as activating factors in mtDAMPs since 
thirteen proteins including cytochrome b encoded in mitochondrial DNA are known to 
be translated in mitochondria as N-formylated forms [40, 41].  
In this chapter, I predicted endogenous N-formylated peptides that are produced 
from mtDNA-encoded proteins and investigated their effects on the functions of 
neutrophilic cells in order to elucidate the possible existence of endogenous 
N-formylated peptides other than MCT-2 for the induction of innate immune responses. 
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III-3. Materials and Methods 
III-3-1. Prediction and synthesis of endogenous N-formylated peptides 
The sequences of thirteen proteins that are encoded in human mtDNA were 
obtained from protein data base SWISS-PROT, and endogenous N-formylated peptides 
other than MCT-2 were basically predicted from those sequences in accordance with the 
information regarding cleavage sites of trypsin or chymotrypsin within N-terminal 
soluble domains of the mtDNA-encoded proteins. The peptides were synthesized by a 
solid-phase method using a 9-fluorenylmethyloxycarbonyl strategy as described in 
Chapter II.  
 
III-3-2. β-Hexosaminidase release and chemotaxis assay 
HL-60 cells (RIKEN Cell Bank, Ibaraki, Japan) were cultured and differentiated 
into neutrophilic/granulocytic cells as described in Chapter II. The ability of peptides on 
the stimulation of β-hexosaminidase release from HL-60 cells differentiated into 
neutrophilic/granulocytic cells was assessed following the method described in Chapter 
II-3-5. 
The chemotactic activity of peptides was measured using ChemotaxiCell 
chambers (pore size of filter membrane: 3 µm; Kurabo, Osaka, Japan) as described 
elsewhere [13, 14]. Briefly, the differentiated cells were washed three times with 
HEPES-buffered Hank’s solution (HBHS; 10 mM HEPES, 136.9 mM NaCl, 5.4 mM 
KCl, 1.2 mM CaCl2, 0.44 mM KH2PO4, 0.49 mM MgCl2, 0.41 mM MgSO4, 0.34 mM 
Na2HPO4, 5.5 mM glucose, 4.2 mM NaHCO3, and 0.1% BSA, pH 7.4) and then 
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resuspended in HBHS to a density of 2 × 106 cells/ml. After preincubation at 37°C for 
10 min, 500 µL of the cell suspension was transferred to a ChemotaxiCell chamber (1 × 
106 cells/chamber). The chambers were placed in each well of a 24-well microplate, in 
which each well contained 1 mL of preheated (37°C) HBHS containing stimulating 
peptides, and incubated at 37°C for 1 h. The chambers were then removed from the 
plate, and the cells in the lower wells were counted. The ability of each peptide to 
induce migration was expressed as a chemotaxis index, which is the number of cells that 
migrated after stimulation divided by the number of cells that migrated after vehicle 
treatment. 
 
III-3-5. Statistical analysis 
Data are expressed as the mean ± standard error (SE) in experiments containing 






III-4-1. Prediction of endogenous N-formylated peptides derived from mtDNA-encoded 
proteins 
I predicted N-formylated peptides presumably produced from mtDNA-encoded 
proteins utilizing the information of cleavage sites for trypsin and chymotrypsin within 
the N-terminal soluble domains as described in “Materials and Methods”. Five 
N-formylated peptides were predicted from cytochrome c oxidase subunit I (COX1), 
and III (COX3), and NADH dehydrogenase subunit 2 (ND2), 4 (ND4), and 5 (ND5) 
(Table III-1). In case of N-formylated peptides derived from cytochrome c oxidase 
subunit II (COX2) and ATP synthase subunit protein 6 (ATP6), it was predicted from 
the information of cleavage sites for chymotrypsin in the transmembrane regions next to 
the N-terminal soluble domains, since COX2 and ATP6 did not have cleavage sites for 
trypsin and chymotrypsin within the N-terminal soluble domains (Table III-1). 
N-formylated peptides derived from NADH dehydrogenase subunit 4L (ND4L) and 6 
(ND6) were also foretold by the information regarding cleavage sites for chymotrypsin 
within the N-terminal transmembrane regions, because ND4L and ND6 did not have 
N-terminal soluble domains (Table III-1). As NADH dehydrogenase subunit 1 (ND1) 
and ATP synthase subunit protein 8 (ATP8) did not contain cleavage sites for trypsin 
and chymotrypsin within the N-terminal soluble domain or the transmembrane region 
next to the N-terminal soluble domain (Table III-1), N-formylated peptides derived from 





Table III-1. N-terminal sequences of thirteen proteins that are encoded in human 
mtDNA, and their cleavage sites of trypsin or chymotrypsin. 
 
 
The red and black arrows indicate the cleavage sites of trypsin (TRY) and chymotrypsin 
(CHY), respectively. The membrane domains of proteins are shown in yellow. The red 





I synthesized an N-formylated peptide derived from NADH dehydrogenase subunit 3 
(ND3) as a N-terminal pentapeptide, because ND3 neither has the N-terminal soluble 
domain nor cleavage sites for trypsin or chymotrypsin within the N-terminal 
transmembrane regions that ND3 has, and an N-terminal decapeptide from ND3 was 
insoluble in physiological buffers. Those predicted N-formylated peptides were shown 
in Table III-2. 
 
III-4-2. β-Hexosaminidase release from neutrophilic/granulocytic differentiated 
HL-60 cells induced by predicted N-formylated peptides  
The ability of predicted peptides as well as MCT-2 to induce β-hexosaminidase 
release from neutrophilic/granulocytic differentiated HL-60 cells was examined to 
elucidate whether those N-formylated peptides can induce neutrophilic functions. As 
described in Chapter II, MCT-2 induced β-hexosaminidase release from differentiated 
HL-60 cells (EC50: MCT-2, 25 ± 2 nM, Figure III-1), and exhibited the maximum 
response at concentrations greater than 1 µM. Similar to MCT-2, COX1(1–13),  
ND4(1–20), ND5(1–28), and ND6(1–6) efficiently induced β-hexosaminidase release 
(EC50’s: COX1 (1–13), 1.8 ± 0.2 nM; ND4 (1–20), 3.3 ± 0.3 nM; ND5 (1–28), 10.2 ± 
1.1 nM; ND6 (1–6), 4.3 ± 0.1 nM, Figure III-1), and their maximum responses were the 
same level that was induced by MCT-2. COX2(1–23), COX3(1–12), ND2(1–10), 

































Figure III-1. β-Hexosaminidase release from differentiated HL-60 cells induced by 
N-formylated peptides predicted from mtDNA-encoded proteins. The ability of each 
peptide to induce β-hexosaminidase release is expressed as a percentage of enzyme 









of the maximum responses as MCT-2, but their EC50 values were significantly higher 
than that of MCT-2 (EC50’s: COX2(1–23), 3,267 ± 123 nM; COX3(1–12), 1,025 ± 95 
nM; ND2(1–10), 420 ± 9 nM; ND3(1–5), 59 ± 4 nM; ND4L(1–5), 483 ± 18 nM, Figure 
III-1). ND1(1–10). ATP6(1–9) also promoted β-hexosaminidase secretion (EC50’s: 
ND1(1–10), >10,000 nM; ATP(1–9), >10,000 nM, Figure III-1), although their 
maximum responses were lower than that of MCT-2. ATP8(1–11) did not induce 
β-hexosaminidase release even at a concentration of 100 µM. 
 
III-4-3. Migration of differentiated HL-60 cells induced by predicted N-formylated 
peptides  
COX1(1–13), ND4(1–20), ND5(1–28), and ND6(1–6) as well as MCT-2 that 
effectively induce β-hexosaminidase release (Figure III-1) were further examined for 
their ability to promote chemotaxis in differentiated HL-60 cells. MCT-2 promoted 
chemotaxis of differentiated HL-60 cells with the maximum response at 10 nM, and the 
promotion was completely desensitized at 1 µM as described previously (14; Figure 
III-2). Similarly, COX1(1–13), ND4(1–20), ND5(1–28), and ND6(1–6) induced the 
chemotaxis in a bell shaped manner. Namely, COX1(1–13) and ND5(1–28) showed the 
maximum responses at 1 nM for the chemotactic stimulation, but the responses were 
completely suppressed at 10 nM and 100 nM, respectively (Figure III-2). ND6(1–6) 








Figure III-2. Migration of differentiated HL-60 cells induced by MCT-2, COX1 (1–13), 
ND4 (1–20), ND5 (1–28), and ND6 (1–6). The activity is expressed as a chemotaxis 
index, which is the number of cells that migrated after stimulation divided by the 
number of cells that migrated after vehicle treatment. Data are expressed as the average 






was completely diminished at 1 µM (Figure III-2). ND4(1–20) promoted the 
chemotaxis with the maximum response at 10 nM, and the induction was completely 
desensitized at 100 nM (Figure III-2). These results demonstrate that predicted peptides 
COX1(1–13), ND4(1–20), ND5(1–28), and ND6(1–6) have the almost same ability to 




Since thirteen proteins including cytochrome b are encoded in mtDNA and 
translated in mitochondria as N-formylated forms [40, 41], it is possible that 
endogenous N-formylated peptides other than MCT-2 are also produced and regulate 
physiological and/or pathophysiological functions in innate immunity. In order to 
evaluate this possibility, putative endogenous N-formylated peptides from the 
mtDNA-encoded proteins were examined for their abilities to activate neutrophilic cells. 
Namely, endogenous N-formylated peptides other than MCT-2 were predicted from 
sequences of the twelve proteins that are encoded in human mtDNA utilizing 
information regarding putative cleavage sites of trypsin and chymotrypsin. Among 
those twelve N-formylated peptides, four peptides derived from COX1, ND4, ND5, and 
ND6, whose primary structures are shown in Table III-2, induced β-hexosaminidase 
release efficiently with the promotion of chemotaxis over the concentration range of 1–
3 nM, 3–30 nM, 1–30 nM, and 1–300 nM, respectively (Figure III-1 and III-2). These 
findings suggest that not only MCT-2 but also those predicted N-formylated peprides 
presumably cleaved from COX1, ND4, ND5, and ND6 regulate innate immune 
responses including neutrophil infiltration and activation. 
It has been shown that mtDAMPs consisting of mitochondria and their contents 
are released into the bloodstream from injured cells in sterile tissue damage sites such as 
trauma and burn [17-23], and the released mtDAMPs induce innate immune responses 
including neutrophil migration and activation [17, 19, 23, 30, 31]. One family of such 
inducing factors is thought to be endogenous N-formylated peptides. MCT-2 should be 
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one of such factors in mtDAMPs, because not only MCT-2 exhibits efficient functional 
abilities to neutrophils but also the presence of its related peptides in mtDAMPs has 
been recently found using a specific monoclonal antibody against MCT-2 [manuscript 
in preparation]. Moreover, it is highly possible that four N-formylated peptides 
COX1(1–13), ND4(1–20), ND5(1–28), and ND6(1–6) that show the potencies 
comparable to MCT-2 also involve innate immunity as activating factors in mtDAMPs. 
For the receptors for such endogenous N-formylated peptides, FPR1 and FPR2 are 
known to be expressed by immune cells including neutrophils and macrophages [36, 38, 
39]. FPR1 and FPR2 are also expressed by a variety of non-immune cells such as 
endothelial cells, epithelial cells, and hepatocytes [39, 56, 61-63, 65], and those 
receptors are suggested to be involved in innate immune responses. Regarding receptor 
preferences of such endogenous N-formylated peptides, MCT-2 has been shown to 
specifically activate FPR2 but not FPR1 as described in Chapter II. Moreover, we have 
also investigated the receptor molecules for COX1(1–13), ND4(1–20), ND5(1–28), and 
ND6(1–6) by the collaboration with Forsman's group at University of Gothenburg; 
ND4(1–20) and ND5(1–28) specifically activate FPR2, whereas ND6(1–6) specifically 
induces the activation of FPR1, and COX1(1–13) promotes the activation of both FPR1 
and FPR2 [66]. However, receptors for those N-formylated peptides may be affected by 
thier molecular forms because the receptor molecule for MCT-2 is shifted from FPR2 to 
FPR1 by the alterations of its molecular forms as shown in Chapter II. The 
physiological roles of endogenous N-formylated peptides and their regulatory 
mechanisms in innate immunity therefore should be investigated with the consideration 
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For a long time, it had been unclear what factors induce initial migration and 
activation of neutrophils after sterile tissue damage such as ischemia reperfusion injury. 
Mitocryptides, a novel family of neutrophil-activating peptides derived from various 
mitochondrial proteins including MCT-1, MCT-2 and MCT-CYC have been purified 
and identified from mammalian tissues for candidate factors that promote such 
immediate neutrophilic functions [13-15]. These mitocryptides can be categorized into 
two groups, that is, N-formylated peptide MCT-2 [14] and non-formylated peptides such 
as MCT-1 and MCT-CYC [13, 15]. Here, I investigated the structure–activity 
relationships of MCT-2 to elucidate how MCT-2 are specifically recognized by its 
receptor molecule FPR2 expressed in neutrophilic cells. I demonstrated that the 
MCT-2(1–7) sequence with an N-formyl group was a minimum structure for the specific 
activation of FPR2. Moreover, it was shown that the receptor of MCT-2 was 
surprisingly shifted from FPR2 to its homologue FPR1 by its physiological C-terminal 
cleavages. These results propose that MCT-2 firstly activates FPR2 to induce 
proinflammatory responses and later promotes delayed responses presumably including 
wound healing/tissue regeneration via FPR1 activation. I also examined the 
physiological existence of endogenous N-formylated peptides other than MCT-2, and 
four N-formylated peptides COX1(1–13), ND4(1–20), ND5(1–28), and ND6(1–6) were 
shown to efficiently induce the migration and phagocytosis of neutrophilic cells with 
potencies comparable to or higher than MCT-2. These findings suggest that those four 
N-formylated peptides are also involved in the regulation of innate immune responses.  
Recently, mitochondrial damage-associated molecular patterns (mtDAMPs) have 
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been focused on as pro-inflammatory factors in innate immunity [17-23]. Indeed, 
mitochondria and their contents are released from various tissues damaged by not only 
sterile inflammation but also bacterial infection for the promotion of innate immune 
responses. One family of such activating factors that induce innate immune responses is 
considered to be endogenous N-formylated peptides. Recently, we found the presence of 
MCT-2-like immunoreactivity in mtDAMPs using a specific monoclonal antibody 
against MCT-2 [manuscript in preparation]. In this thesis, I showed that not only MCT-2 
but also ND6(1–6), ND5(1–28), ND4(1–20), and COX1(1–13) exhibited efficient 
potencies in neutrophilic migration and activation. These findings suggest that those 
N-formylated peptides including MCT-2 are peptidergic factors that induce innate 
immune responses in mtDAMPs. 
Although it is suggested the physiological roles of N-formylated peptides 
including MCT-2 in mtDAMPs, are the peptidergic factors contained in mtDAMPs only 
N-formylated peptides? As described above, non-formylated peptides MCT-1 and 
MCT-CYC can also efficiently induce not only neutrophilic chemotaxis but also 
phagocytosis at nanomolar concentrations [13, 15]. Moreover, it was found that most 
fragmented peptides derived from mitochondrial transit sequences in nuclear-encoded 
mitochondrial proteins showed the abilities to induce neutrophil migration and 
activation efficiently [16]. Recently, it was also observed that the mixture of these 
mitocryptides at the concentrations that do not cause the stimulation by each peptide 
markedly induced phagocytosis in neutrophilic cells, suggesting that neutrophils are 
concertedly activated by accumulation of various mitocryptides [67]. This synergistic 
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signaling mechanism has been designated as "accumulative signaling" [67, 68]. These 
findings suggest the hypothesis that abundant accumulation of various mitocryptides 
existing in mtDAMPs concertedly causes severe and complicated 
inflammation-associated neutrophilic functions. Thus, it is important to investigate the 
involvement of N-formylated mitocryptides and non-formylated ones in not only sterile 
inflammation but also bacterial infection for the elucidation of the complete figure of 
the "very" early stage of innate immune responses. We are now attempting to elucidate 
physiological and pathophysiological roles of those mitocryptides utilizing their specific 
neutralizing monoclonal antibodies [68-70]. We are also investigating the signaling 
mechanisms promoted by various mitocryptides including dynamic cellular movements 
of receptors and signaling molecules [71-75]. The elucidation of not only physiological 
and pathophysiological roles but also signaling mechanisms concerning those 
mitocryptides are expected to provide therapeutic breakthrough for various 
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